JP2025105966A5 - - Google Patents

Info

Publication number
JP2025105966A5
JP2025105966A5 JP2025077117A JP2025077117A JP2025105966A5 JP 2025105966 A5 JP2025105966 A5 JP 2025105966A5 JP 2025077117 A JP2025077117 A JP 2025077117A JP 2025077117 A JP2025077117 A JP 2025077117A JP 2025105966 A5 JP2025105966 A5 JP 2025105966A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
component
solvate
salt
pemafibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025077117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025105966A (ja
Filing date
Publication date
Priority claimed from JP2019237733A external-priority patent/JP2020105174A/ja
Application filed filed Critical
Publication of JP2025105966A publication Critical patent/JP2025105966A/ja
Publication of JP2025105966A5 publication Critical patent/JP2025105966A5/ja
Pending legal-status Critical Current

Links

JP2025077117A 2018-12-27 2025-05-07 医薬組成物 Pending JP2025105966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018244282 2018-12-27
JP2018244282 2018-12-27
JP2019237733A JP2020105174A (ja) 2018-12-27 2019-12-27 医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019237733A Division JP2020105174A (ja) 2018-12-27 2019-12-27 医薬組成物

Publications (2)

Publication Number Publication Date
JP2025105966A JP2025105966A (ja) 2025-07-10
JP2025105966A5 true JP2025105966A5 (https=) 2026-02-13

Family

ID=71448316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019237733A Pending JP2020105174A (ja) 2018-12-27 2019-12-27 医薬組成物
JP2025077117A Pending JP2025105966A (ja) 2018-12-27 2025-05-07 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019237733A Pending JP2020105174A (ja) 2018-12-27 2019-12-27 医薬組成物

Country Status (1)

Country Link
JP (2) JP2020105174A (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
EA009374B1 (ru) * 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
CA2694378A1 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
ES2752039T3 (es) * 2012-09-27 2020-04-02 Kowa Co Agente terapéutico para la dislipidemia
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
CN106232144B (zh) * 2014-03-18 2019-12-06 武田药品工业株式会社 固体分散体

Similar Documents

Publication Publication Date Title
JP2024014994A5 (https=)
ME00318B (me) Nova kompozicija i njena upotreba
HRP20250258T1 (hr) Farmaceutska kombinacija, pripravak, i kombinirana priprema koja sadrži aktivator glukokinaze i inhibitor dpp-iv te metode pripreme, i njihova uporaba
KR101473268B1 (ko) 클로피도그렐과 아스피린을 포함하는 약학 조성물 및 그의 제조방법
JP6160263B2 (ja) ロキソプロフェン含有医薬組成物
JP2025105966A5 (https=)
JPS5982311A (ja) セフアレキシン持効性製剤
KR101801064B1 (ko) 위장질환 치료용 삼중층 정제
JP6084355B2 (ja) アンブロキソール含有製剤粒子
JPWO2020178878A5 (https=)
EP2988735B1 (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
WO2010027010A1 (ja) 有効成分が境界を有してなる医薬固形製剤
CN1726011A (zh) 稳定的多比拉米制剂
CN103127023B (zh) 一种盐酸度洛西汀肠溶片及其制备方法
WO2014013928A1 (ja) 安定化された内服用固形製剤
JP6114573B2 (ja) ロキソプロフェンナトリウムと制酸剤を含有する固形製剤
JP6106359B2 (ja) ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
EP2915528A1 (en) Vildagliptin formulation process under inert gas atmosphere
PT1762231E (pt) Microcomprimidos de magnésio de libertação retardada
JP6366547B2 (ja) 光安定性が向上した、プラミペキソール製剤包装体
TWI753097B (zh) 口服甲狀腺治療劑
JP6149625B2 (ja) 医薬組成物
JP2020105108A (ja) 糖衣錠
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
CA2284705A1 (en) Chemically and thermally stable norastemizole formulations